{{scheme.chgp}}%
{{scheme.chgp}}%
No Matches Found
{{scheme.chgp}}%
No Matches Found
No Matches Found
Quest Diagnostics, Inc.
Is Quest Diagnostics, Inc. technically bullish or bearish?
As of October 3, 2025, Quest Diagnostics has a mildly bullish technical trend, supported by bullish MACD and moving averages, while outperforming the S&P 500 year-to-date and over the past year, despite mixed signals in longer-term performance.
Is Quest Diagnostics, Inc. technically bullish or bearish?
As of October 3, 2025, Quest Diagnostics, Inc. shows a mildly bullish trend with positive MACD and moving averages, despite recent underperformance against the S&P 500 in the short term.
Is Quest Diagnostics, Inc. technically bullish or bearish?
As of October 3, 2025, Quest Diagnostics has a mildly bullish technical trend, supported by bullish MACD and KST indicators, despite recent underperformance compared to the S&P 500.
Quest Diagnostics Hits New 52-Week High at $191.45, Surges 34.71%
Quest Diagnostics, Inc. has achieved a new 52-week high, reflecting its strong market performance with a notable annual increase. The company, with a market capitalization of approximately USD 29.72 billion, maintains a solid valuation and a commitment to shareholder returns through a significant dividend yield.
Quest Diagnostics Hits New 52-Week High of $189.23, Reflecting Strong Performance
Quest Diagnostics, Inc. achieved a new 52-week high of USD 189.23 on September 26, 2025, reflecting strong market performance with a 33.59% increase over the past year. The company, with a market cap of USD 29,720 million, features a P/E ratio of 28.00 and a dividend yield of 87.16%.
Quest Diagnostics Hits New 52-Week High at $187.96, Surpassing Previous Low
Quest Diagnostics, Inc. achieved a new 52-week high of USD 187.96 on September 23, 2025, reflecting strong market performance with a 32.16% increase over the past year. The company, with a market cap of USD 29,720 million, demonstrates solid financial health through various metrics, including a notable dividend yield.
Is Quest Diagnostics, Inc. technically bullish or bearish?
As of September 11, 2025, Quest Diagnostics, Inc. shows a bullish technical trend with strong indicators across multiple time frames, outperforming the S&P 500 year-to-date, though it has underperformed over the longer term.
Is Quest Diagnostics, Inc. overvalued or undervalued?
As of June 30, 2025, Quest Diagnostics is fairly valued with a P/E ratio of 28, an EV to EBITDA of 17.29, and a Price to Book Value of 4.09, while achieving a year-to-date return of 21.52%, outperforming the S&P 500's 12.22%.
Is Quest Diagnostics, Inc. overvalued or undervalued?
As of June 5, 2025, Quest Diagnostics, Inc. is fairly valued with a P/E ratio of 28, an EV to EBITDA of 17.29, and a PEG ratio of 9.40, showing competitive positioning within its sector despite a strong stock return of 29.33% over the past year.
Is Quest Diagnostics, Inc. technically bullish or bearish?
As of June 10, 2025, the technical trend is bullish, supported by strong indicators like the MACD and Bollinger Bands, despite a mixed signal from the RSI.
Who are in the management team of Quest Diagnostics, Inc.?
As of March 2022, the management team of Quest Diagnostics, Inc. includes Stephen Rusckowski (Chairman, President, and CEO), Dr. Daniel Stanzione (Lead Independent Director), and several Independent Directors: Vicky Gregg, Wright Lassiter, Timothy Main, and Denise Morrison. They oversee the company's strategic direction and operations.
What does Quest Diagnostics, Inc. do?
Quest Diagnostics, Inc. is a mid-cap provider of diagnostic information services, with recent net sales of $2.65 billion and a net profit of $234 million. Key financial metrics include a P/E ratio of 28.00 and a dividend yield of 117.62%.
How big is Quest Diagnostics, Inc.?
As of Jun 18, Quest Diagnostics, Inc. has a market capitalization of $29.1 billion, with recent net sales of $10.2 billion and a net profit of $943 million.
{{list.post_title}}
{{list.post_excerpt}}
{{list.post_title}}
{{list.post_excerpt}}
